Galacteros F, Amaudric F, Prehu C, Feingold J, Doucet-Populaire F, Sobel A; International Conference on AIDS.
Int Conf AIDS. 1991 Jun 16-21; 7: 209 (abstract no. W.B.2108).
INSERM U91 CHU Henri Mondor Creteil France
OBJECTIVE: Anemia is a common, multifactorial, complication of both AIDS and zidovudine therapy. It may reveal acquired abnormalities of globin chain synthesis. METHODS: We have investigated disorders of hemoglobin synthesis in 125 patients being at different stages of the disease (CDC 1987) and free of hereditary hemoglobin disorders. RESULTS: Among 72 individuals which were studied before AZT therapy, 42 were classified stage II and III and 30 stage IV. Significant differences were seen in HbA2 concentrations (in percent or pg) and not in HbF levels between these subgroups: stage IV untreated patients had elevated HbA2. 14 patients were studied before and after at least 2 months of AZT treatment. Highly significant differences in HbA2 concentrations were observed, all HbA2 concentrations being over the upper limit of normal range after treatment. HbF levels although higher after treatment did not reach statistical significance because of large variance. For 13 patients of which 3 received AZT therapy we measured globin chain biosynthetic ratios. The results were stage, not treatment, dependent: those in stage II and III had normal alpha/beta globin chain ratios; stage IV patients had globin chain ratios between 1.34 and 3.95. DISCUSSION AND CONCLUSIONS: A beta Thalassemia like disturbance of hemoglobin synthesis is present during HIV-1 infection at later stage and most prominantly after AZT therapy. This phenomenon may contribute to produce anemia in this clinical condition.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Anemia
- Centers for Disease Control and Prevention (U.S.)
- Disease Progression
- Fetal Hemoglobin
- Globins
- HIV Infections
- Hemoglobins
- Humans
- United States
- Zidovudine
- beta-Thalassemia
- therapy
Other ID:
UI: 102192697
From Meeting Abstracts